Your browser doesn't support javascript.
loading
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda, William G; Brown, Jennifer; Abramson, Jeremy S; Awan, Farrukh; Bilgrami, Syed F; Bociek, Greg; Brander, Danielle; Chanan-Khan, Asher A; Coutre, Steve E; Davis, Randall S; Eradat, Herbert; Fletcher, Christopher D; Gaballa, Sameh; Ghobadi, Armin; Hamid, Muhammad Saad; Hernandez-Ilizaliturri, Francisco; Hill, Brian; Kaesberg, Paul; Kamdar, Manali; Kaplan, Lawrence D; Khan, Nadia; Kipps, Thomas J; Ma, Shuo; Mato, Anthony; Mosse, Claudio; Schuster, Stephen; Siddiqi, Tanya; Stephens, Deborah M; Ujjani, Chaitra; Wagner-Johnston, Nina; Woyach, Jennifer A; Ye, J Christine; Dwyer, Mary A; Sundar, Hema.
Afiliación
  • Wierda WG; The University of Texas MD Anderson Cancer Center.
  • Brown J; Dana-Farber/Brigham and Women's Cancer Center.
  • Abramson JS; Massachusetts General Hospital Cancer Center.
  • Awan F; UT Southwestern Simmons Comprehensive Cancer Center.
  • Bilgrami SF; Yale Cancer Center/Smilow Cancer Hospital.
  • Bociek G; Fred & Pamela Buffett Cancer Center.
  • Brander D; Duke Cancer Institute.
  • Chanan-Khan AA; Mayo Clinic Cancer Center.
  • Coutre SE; Stanford Cancer Institute.
  • Davis RS; O'Neal Comprehensive Cancer Center at UAB.
  • Eradat H; UCLA Jonsson Comprehensive Cancer Center.
  • Fletcher CD; University of Wisconsin Carbone Cancer Center.
  • Gaballa S; Moffitt Cancer Center.
  • Ghobadi A; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Hamid MS; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
  • Hernandez-Ilizaliturri F; Roswell Park Comprehensive Cancer Center.
  • Hill B; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Kaesberg P; UC Davis Comprehensive Cancer Center.
  • Kamdar M; University of Colorado Cancer Center.
  • Kaplan LD; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Khan N; Fox Chase Cancer Center.
  • Kipps TJ; UC San Diego Moores Cancer Center.
  • Ma S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Mato A; Memorial Sloan Kettering Cancer Center.
  • Mosse C; Vanderbilt-Ingram Cancer Center.
  • Schuster S; Abramson Cancer Center at the University of Pennsylvania.
  • Siddiqi T; City of Hope National Medical Center.
  • Stephens DM; Huntsman Cancer Institute at the University of Utah.
  • Ujjani C; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
  • Wagner-Johnston N; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Woyach JA; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Ye JC; University of Michigan Rogel Cancer Center; and.
  • Dwyer MA; National Comprehensive Cancer Network.
  • Sundar H; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 20(6): 622-634, 2022 06.
Article en En | MEDLINE | ID: mdl-35714675
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Linfoma de Células B / Antineoplásicos Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Natl Compr Canc Netw Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Linfoma de Células B / Antineoplásicos Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Natl Compr Canc Netw Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article